Guardant Health Inc. has announced the expansion of its Guardant Reveal blood test to include late-stage therapy response monitoring for patients with solid tumors. The expanded test leverages Guardant's proprietary epigenomic technology to track over 20,000 methylation signals and measure changes in circulating tumor DNA (ctDNA) levels, offering a tissue-free method to monitor treatment response and detect early disease progression. Recent clinical studies have supported this expansion: the first clinical-validation study of pan-cancer chemotherapy monitoring, published in The Journal of Liquid Biopsy, found that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures. Additionally, the RADIOHEAD study demonstrated the test's ability to detect responses to immunotherapy up to five months earlier than standard imaging. Results from these studies have already been presented. The company has also introduced a universal ordering option to streamline access to its portfolio of products.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251110372022) on November 10, 2025, and is solely responsible for the information contained therein.
Comments